TCGA-44-2665-01B-06R-A277-07
— · cohortMD2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD2
- subtype
- cohortMD2
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.370
- PROTEIN_SECRETION+0.280
- ANDROGEN_RESPONSE+0.240
- HEDGEHOG_SIGNALING+0.210
- KRAS_SIGNALING_UP+0.190
- TGF_BETA_SIGNALING+0.150
- MITOTIC_SPINDLE+0.100
- IL2_STAT5_SIGNALING+0.030
- IL6_JAK_STAT3_SIGNALING+0.030
- INFLAMMATORY_RESPONSE+0.030
Top 10 suppressed
- MYC_TARGETS_V2-0.610
- OXIDATIVE_PHOSPHORYLATION-0.570
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.500
- DNA_REPAIR-0.440
- CHOLESTEROL_HOMEOSTASIS-0.410
- MYC_TARGETS_V1-0.410
- UV_RESPONSE_UP-0.410
- P53_PATHWAY-0.400
- E2F_TARGETS-0.370
- GLYCOLYSIS-0.370
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | ba2b0b86-f7f1-47f7-b0fd-bec3f623febb | — | — | 0.950 |
| 2 | TCGA-A7-A26E-01B-06R-A277-07 | — | D | 0.911 |
| 3 | d1447a31-64bb-4e70-ae50-eeff7a605f38 | — | — | 0.904 |
| 4 | TCGA-A7-A13E-01B-06R-A277-07 | — | D | 0.895 |
| 5 | TCGA-A7-A0DB-01C-02R-A277-07 | — | D | 0.885 |
| 6 | TCGA-AC-A3QQ-01B-06R-A22O-07 | — | D | 0.882 |
| 7 | b8135e73-31c3-49af-b4da-a7ed5f28d68a | — | — | 0.881 |
| 8 | 5abd486a-6aed-4dcf-a2a2-2537af6cdd9c | — | — | 0.881 |
| 9 | AUR-AFUM-TTP1-A-1-0-R-A741-41 | — | D | 0.879 |
| 10 | SRR4195677 | — | — | 0.878 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.150 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.030 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.030 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.030 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.020 | Cobimetinib | — uncovered |